{'fraction_non_alphanumeric': 0.03909465020576132, 'fraction_numerical': 0.027777777777777776, 'mean_word_length': 4.497175141242938, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
CAFFEINE AND THEOPHYLLINE METABOLISM IN OLDER PRETERM INFANTS

Because there has been a dearth of data regarding caffeine and theophylline pharmacokinetics in older preterm infants, we studied 17 premature infants with apnea at an age of 15-38 days (G.A.=29.7±1.9 wks, M±SD). They received oral or IV caffeine at a dose of 2.3 to 10.3 mg/kg/day (x=4.9±1.8) once or twice daily. To 25 μl of plasma an equal amount of acetonitrile was added. After vortex and ultracentrifugation, 15 μl of supernatant were injected into a reverse phase HPLC column and monitored at 280 nm. β-hydroxyethyltheophylline was the internal standard.Results are as follows:We found no correlation between gestational age, weight, age, or dose and caffeine or theophylline levels. It was significant that on similar doses, patients on a twice a day schedule had much higher peak and trough levels than on one dose/day. We now use BID doses for caffeine therapy because of the higher levels attained.